Hangzhou Tigermed Consulting Co., Ltd (HKG:3347)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
39.85
+1.35 (3.51%)
Jul 3, 2025, 2:46 PM HKT
44.38%
Market Cap 47.88B
Revenue (ttm) 6.98B
Net Income (ttm) 359.76M
Shares Out n/a
EPS (ttm) 0.42
PE Ratio 133.10
Forward PE 39.12
Dividend 0.32 (0.84%)
Ex-Dividend Date Jun 12, 2025
Volume 2,967,900
Average Volume 5,576,611
Open 39.00
Previous Close 38.50
Day's Range 38.15 - 40.10
52-Week Range 22.30 - 58.80
Beta 0.78
RSI 59.79
Earnings Date Aug 25, 2025

About HKG:3347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito... [Read more]

Sector Healthcare
Founded 2004
Employees 10,185
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 3347
Full Company Profile

Financial Performance

In 2024, HKG:3347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.